[HTML][HTML] Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma

BM Lee, J Seong - World Journal of Gastroenterology, 2021 - ncbi.nlm.nih.gov
In the immune oncology era, the clinical efficacy of immune checkpoint inhibitors (ICIs)
against most solid cancers is well known. In hepatocellular carcinoma, the recent success of …

Real-world, long-term outcomes of nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck and impact of the magnitude of best …

T Matsuki, I Okamoto, C Fushimi, H Takahashi… - Cancers, 2020 - mdpi.com
Simple Summary No real-world, long-term outcomes of immunotherapy with nivolumab for
recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have …

Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer

XL Wei, JY Xu, DS Wang, DL Chen… - … in medical oncology, 2021 - journals.sagepub.com
Background: We previously reported tumor mutation burden (TMB) as a potential prognostic
factor for patients with advanced gastric cancer (AGC) receiving immunotherapy. We aimed …

Real-world therapeutic outcomes of the pembrolizumab regimen as first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck: a single …

D Sano, M Tokuhisa, H Takahashi, T Hatano… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: This Japanese single-center retrospective cohort study aimed to evaluate
the real-world therapeutic outcomes of pembrolizumab or pembrolizumab plus …

Impact of lymphopenia on efficacy of nivolumab in head and neck cancer patients

M Césaire, A Rambeau, F Clatot, A Johnson… - European Archives of …, 2023 - Springer
Introduction Lymphopenia has been correlated with poorer survival in patients with
metastatic cancers treated with anti-PD-1 immunotherapy. Treatments such as …

Avelumab first‐line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN …

J Manitz, A Gerhold‐Ay, P Kieslich, P Shah… - Cancer …, 2024 - Wiley Online Library
Background Avelumab first‐line (1 L) maintenance is a standard of care for advanced
urothelial carcinoma (aUC) based on the JAVELIN Bladder 100 phase 3 trial, which showed …

Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma

I Okamoto, K Tsukahara, H Sato - Scientific Reports, 2022 - nature.com
Nivolumab, an immune checkpoint inhibitor, is beneficial to patients with platinum-refractory
recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC). However …

Prediction of tumor regression grade in far-advanced gastric cancer after preoperative immuno-chemotherapy using dual-energy CT-derived extracellular volume …

Y Chen, J Jiang, C Yan, J Jiang, B Shi, Z Xu, F Yuan… - European …, 2024 - Springer
Objectives This study examines the effectiveness of dual-energy CT (DECT) delayed-phase
extracellular volume (ECV) fraction in predicting tumor regression grade (TRG) in far …

Positron emission tomography-computed tomography parameters predict efficacy of immunotherapy in head and neck squamous cell carcinomas

S Zhang, R Zhang, W Gong, C Wang, C Zeng… - Frontiers in …, 2021 - frontiersin.org
Background This study aims to assess the association between positron emission
tomography-computed tomography (PET-CT) parameters and the response to immune …

Unconventional radiotherapy to enhance immunotherapy efficacy in bulky tumors: A case report

M Massaccesi, L Boldrini, A Romano, E Rossi… - …, 2021 - Taylor & Francis
Determining the most appropriate management strategy for patients with large tumor
masses is a very challenging issue. Unconventional radiotherapy modalities, such as …